Aaron Ciechanover
Overview
Explore the profile of Aaron Ciechanover including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
172
Citations
11783
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gottfried Y, Lulu-Shimron C, Goldhirsh G, Fisher Y, Ziv T, Hoon D, et al.
Biochem Biophys Res Commun
. 2024 Dec;
745:151231.
PMID: 39732122
The ubiquitin proteasome system (UPS), driven by ubiquitin as a degradation signal, eliminates, in a highly specific manner, 'abnormal' proteins and proteins that completed their function. This process involves a...
2.
Kravtsova-Ivantsiv Y, Goldhirsh G, Ciechanover A
Proc Natl Acad Sci U S A
. 2024 Dec;
121(52):e2416909121.
PMID: 39689179
Cytokines constitute a family of proteins that modulate the immune system and are secreted by many cells. CXCL12, along with its receptor CXCR4, are essential players in numerous processes. Dysregulation...
3.
Fu A, Luo Z, Ziv T, Bi X, Lulu-Shimron C, Cohen-Kaplan V, et al.
Proc Natl Acad Sci U S A
. 2024 Oct;
121(43):e2414377121.
PMID: 39418304
Liquid-liquid phase separation has emerged as a crucial mechanism driving the formation of membraneless biomolecular condensates, which play important roles in numerous cellular processes. These condensates, found both in the...
4.
Zhou J, Sang X, Wu M, Qian T, Ciechanover A, An J, et al.
ACS Med Chem Lett
. 2024 Oct;
15(10):1741-1748.
PMID: 39411540
Many reported proteasome inhibitors, including the three clinically approved inhibitors, bortezomib, carfilzomib, and ixazomib, have peptidic structures. In this study, using a hybrid and versatile strategy for covalent virtual screening...
5.
Livneh I, Fabre B, Goldhirsh G, Lulu C, Zinger A, Shammai Vainer Y, et al.
Cell Death Differ
. 2024 Sep;
31(10):1242-1254.
PMID: 39266717
The proteasome, the catalytic arm of the ubiquitin system, is regulated via its dynamic compartmentation between the nucleus and the cytoplasm, among other mechanisms. Under amino acid shortage, the proteolytic...
6.
Boulos A, Maroun D, Ciechanover A, Ziv N
Commun Biol
. 2024 Aug;
7(1):1014.
PMID: 39155290
Huntington's disease (HD) is caused by a glutamine repeat expansion in the protein huntingtin. Mutated huntingtin (mHtt) forms aggregates whose impacts on neuronal survival are still debated. Using weeks-long, continual...
7.
Cech T, Charpentier E, Ciechanover A, Lefkowitz R, Wuthrich K
Cell Chem Biol
. 2024 Aug;
31(8):1388-1390.
PMID: 39151404
Since the first award in 1901, the Nobel Prize has come to signify the pinnacle of scientific achievement. In this Voices piece in the August special issue of Cell Chemical...
8.
Primorac D, Ciechanover A
Croat Med J
. 2024 Jun;
65(3):169-173.
PMID: 38868962
No abstract available.
9.
Neeman-Egozi S, Livneh I, Dolgopyat I, Nussinovitch U, Milman H, Cohen N, et al.
Int J Mol Sci
. 2024 May;
25(9).
PMID: 38732146
The ubiquitin-proteasome system (UPS) is an essential mechanism responsible for the selective degradation of substrate proteins via their conjugation with ubiquitin. Since cardiomyocytes have very limited self-renewal capacity, as they...
10.
Beyar R, Blazer S, Breuer E, Carmi R, Ciechanover A, Clarfield A, et al.
Lancet
. 2024 Feb;
403(10430):905.
PMID: 38373434
No abstract available.